UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2024

Commission File Number: 001-40858

XORTX Therapeutics Inc.

3710 – 33rd Street NW, Calgary, Alberta, T2L 2M1

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

    XORTX Therapeutics Inc.    
     (Registrant)
       
     
Date: September 13, 2024   By:      /s/ Allen Davidoff    
    Name:  Allen Davidoff
    Title:  Chief Executive Officer
     

EXHIBIT INDEX

99.1   Report of Voting Results
 

Exhibit 99.1

 

XORTX THERAPEUTICS INC.

 

Report of Voting Results
(Section 11.3 of National Instrument 51-102)

 

In accordance with section 11.3 of National Instrument 51-102 - Continuous Disclosure Obligations, this report briefly describes the matters voted upon and the outcome of the votes at the Annual General and Special Meeting of Shareholders of XORTX Therapeutics Inc. (the “Company”) held on September 12, 2024 at the offices of the Company (the “Meeting”).

 

1.Setting the Number of Directors at Seven

 

A resolution setting the number of directors of the board to seven was approved. Proxies were received as follows:

 

For the Motion:

 608,344 (68.430%)
Against: 280,652 (31.570%)

 

2.Election of Directors

 

The shareholders voted by way of proxy and the following nominees were elected as directors to serve until the next annual meeting of shareholders of the Company or until their successors are duly elected or appointed:

 

Director Votes For Votes Withheld
Allen Davidoff 572,504 79.124% 151,052 20.876%
William Farley 533,046 73.670% 190,510 26.330%
Anthony J. Giovinazzo 487,453 67.369% 236,103 32.631%
Abigail Jenkins 544,124 75.201% 179,432 24.799%
Raymond Pratt 543,446 75.108% 180,110 24.892%
Patrick Treanor 529,118 73.127% 194,438 26.873%
Paul Van Damme 546,083 75.472% 177,473 24.538%

 

3.Appointment of Auditors

 

A resolution appointing Smythe LLP Chartered Professional Accountants, as auditor of the Company until the next annual meeting of shareholders and authorizing the directors of the Company to fix the auditor's remuneration was approved. Proxies were received as follows:

 

For the Motion: 739,390 (83.171%)
Withheld: 149,606 (16.829%)

 

4.Re-Approval of Stock Option Plan

 

A resolution re-approving and confirming the Company’s stock option plan as described in the management information circular dated August 9, 2024, including that the maximum number of common shares reserved for issuance under the stock option plan at any given time is equal to ten percent (10%) of the issued and outstanding common shares as at the date of grant of an option under the stock option plan, was approved. Proxies were received as follows:

 

For the Motion: 457,824 (63.274%)
Against: 265,732 (36.726%)

 

For additional information, please see the Company’s notice of meeting and information circular dated August 9, 2024 filed on SEDAR in connection with the Meeting.

 

DATED at Calgary, AB, September 13, 2024.

 

 

XORTX THERAPEUTICS INC.

 

/s/ Charlotte May

  Charlotte May
Corporate Secretary

 

 

XORTX Therapeutics (NASDAQ:XRTX)
Historical Stock Chart
Von Dez 2024 bis Jan 2025 Click Here for more XORTX Therapeutics Charts.
XORTX Therapeutics (NASDAQ:XRTX)
Historical Stock Chart
Von Jan 2024 bis Jan 2025 Click Here for more XORTX Therapeutics Charts.